
Claims

1. ~~A method of treating a hematological malignancy, comprising administering to a subject~~ Use of a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor ~~and a DNA demethylating agent~~in the manufacture of a medicament for treating a hematological malignancy in a subject, wherein the mutant IDH2 is to be administered to the subject with a DNA demethylating agent, the mutant IDH2 inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:



or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1), and wherein the hematological malignancy is a malignancy characterized by the presence of a mutant allele of IDH2.


2. The ~~method~~use of claim 1, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.

3. The ~~method~~use of claims 1 or 2, wherein the malignancy is acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, lymphoma (e.g., T-cell lymphoma or B-cell lymphoma), angioimmunoblastic T-cell lymphoma (AITL) or blastic plasmacytoid dendritic cell neoplasm.

4. The ~~method~~use of any one of claims 1 to 3, wherein the malignancy is acute myelogenous leukemia.

5. The ~~method~~use of claim 4, wherein the acute myelogenous leukemia newly diagnosed.

6. Use of ~~A method of treating a solid tumor, comprising administering to a subject~~ a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor ~~and a DNA demethylating agent~~in the manufacture of a medicament for treating a solid tumor in a subject, wherein the mutant IDH2 inhibitor is to be administered to the subject with and a DNA demethylating agent and the mutant IDH2 is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:




or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof thereof (COMPOUND 1), and wherein the solid tumor is characterized by the presence of a mutant allele of IDH2.

7. The ~~method~~use of any one of claims 1 to 6, wherein the dose of COMPOUND 1 is about 20 to 2000 mg/day.

8. The ~~method~~use of any one of claims 1 to 7, wherein the dose of COMPOUND 1 is about 50 to 500 mg/day.

9. The ~~method~~use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 50 mg/day.

10. The ~~method~~use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 100 mg/day.

11. The ~~method~~use of any one of claims 1 to 8, wherein the dose of COMPOUND 1 is about 200 mg/day.

12. The ~~method~~use of any one of claims 1 to 11, wherein the DNA demethylating agent is azacitidine.

13. The ~~method~~use of any one of claims 1 to 12, wherein the dose of azacitidine is ~~about~~ 50 to ~~about~~ 500 mg/m$^2$.

14. The ~~method~~use of any one of claims 1 to 13, wherein the dose of azacitidine is ~~about~~ 50 to ~~about~~ 200 mg/m$^2$.

15. The ~~method~~use of any one of claims 1 to 13, wherein the dose of azacitidine is about 50 mg/m$^2$.

16. The ~~method~~use of any one of claims 1 to 13, wherein the dose of azacitidine is about 60 mg/m$^2$.

17. The ~~method~~use of any one of claims 1 to 13, wherein the dose of azacitidine is about 75 mg/m$^2$.


18. The ~~method~~use of any one of claims 1 to 17, wherein COMPOUND 1 and azacitidine are to be administered concurrently.

19. The ~~method~~use of any one of claims 1 to 17, wherein COMPOUND 1 and azacitidine are to be administered sequentially.

20. A pharmaceutical composition, comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof thereof , and azacitidine.

21. The ~~method~~ use of claim 4, wherein the malignancy is acute myelogenous leukemia and wherein ~~the method comprises aministering to a patient~~ the composition of claim 20 is to be administered to the patient.

~~22. A mutant isocitrate dehydrogenase 2 (IDH2) inhibitor for use in a method for treating a hematological malignancy, comprising administering to a subject said mutant IDH2 inhibitor and a DNA demethylating agent, wherein the mutant IDH2 inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:~~



or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1), and wherein the hematological malignancy is a malignancy characterized by the presence of a mutant allele of IDH2.


23. The mutant IDH2 inhibitor for use of claim 22, wherein the IDH2 mutation is an IDH2 R140Q or R172K mutation.

24. The mutant IDH2 inhibitor for use of claim 22 or 23, wherein the malignancy is acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloid sarcoma, multiple myeloma, lymphoma (e.g., T-cell lymphoma or B-cell lymphoma), angioimmunoblastic T-cell lymphoma (AITL) or blastic plasmacytoid dendritic cell neoplasm.

25. The mutant IDH2 inhibitor for use of claims 22 to 24, wherein the malignancy is acute myelogenous leukemia.

26. The use of claim 25, wherein the acute myelogenous leukemia newly diagnosed.

27. A mutant IDH2 inhibitor for use in a method of treating a solid tumor, comprising administering to a subject said mutant IDH2 inhibitor and a DNA demethylating agent, wherein the mutant IDH2 inhibitor is 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:



~~or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof thereof (COMPOUND 1), and wherein the solid tumor is characterized by the presence of a mutant allele of IDH2.~~

~~28. The mutant IDH2 inhibitor for use of claims 20 to 27, wherein the dose of COMPOUND 1 is about 20 to 2000 mg/day; preferably about 50 to 500 mg/day; preferably about 50 mg/day; preferably about 100 mg/day; or preferably about 200 mg/day.~~

~~29. The mutant IDH2 inhibitor for use of claims 22 to 28, wherein the DNA demethylating agent is azacitidine; preferably wherein the dose of azacitidine is about 50 to about 500 mg/m$^2$; preferably about 50 to about 200 mg/m$^2$; preferably about 50 mg/m$^2$; preferably about 60 mg/m$^2$; or preferably about 75 mg/m$^2$.~~

~~30. The mutant IDH2 inhibitor for use of claims 22 to 29, wherein COMPOUND 1 and azacitidine are administered concurrently; or wherein COMPOUND 1 and azacitidine are administered sequentially.~~

~~31. A pharmaceutical composition, comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof thereof , and azacitidine.~~

~~32. The mutant IDH2 inhibitor for use of claim 31, wherein the malignancy is acute myelogenous leukemia (AML) and wherein the method comprises aministering to a patient the pharmaceutical composition of claim 35.~~